Dark

MTNB
Matinas BioPharma Holdings, Inc.
stock NYSEAMERICAN

At Close

Jul 2, 2025 3:58:30 PM EDT

0.9355USD-0.479%(-0.0045)13,169

0.00Bid 0.00Ask 0.0000Spread

Pre-market

Jul 3, 2025 8:00:30 AM EDT

0.9355USD-0.479%(-0.0045)217

After-hours

Jul 3, 2025 4:27:30 PM EDT

0.9101USD-2.715%(-0.0254)633

OverviewHistoricalExchangesShortsNews

Jan 25, 2022

06:30AM EST End of Phase 2 Meeting with FDA Provides Pathway to NDA Submission for MAT2203 Following Confirmatory Data to be Generated in an Additional Cohort; Cohort 5 in Ongoing EnACT Trial GlobeNewswire Inc

Jan 18, 2022

07:00AM EST Matinas BioPharma to Provide Corporate Update and 2022 Business GlobeNewswire Inc

Dec 16, 2021

06:35AM EST Matinas BioPharma Announces Unanimous DSMB Approval To Progress Into Fourth And Final Cohort Of Patients In The EnACT Trial Of MAT2203 For The Treatment Of Cryptococcal Meningitis Benzinga

06:30AM EST DSMB evaluated both safety and efficacy data in recommending cohort progression GlobeNewswire Inc

Dec 6, 2021

06:30AM EST Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical companyfocused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced the appointment of Thomas Hoover to the newly created position of Chief Business Officer. GlobeNewswire Inc

Nov 18, 2021

07:00AM EST Matinas BioPharma to Participate in 33rd Annual Piper Sandler GlobeNewswire Inc

Nov 8, 2021

06:44AM EST Matinas BioPharma Q3 Loss Attributable To Shareholders $6.8 Mln Or $0.03/Shr Vs Loss $5.7 Mln Or $0.03/Shr Last Eyar RTTNews

06:36AM EST Matinas BioPharma Hldgs Q3 EPS $(0.03) Misses $(0.02) Estimate Benzinga

06:35AM EST Positive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis;DSMB unanimously recommended progression to second half of study GlobeNewswire Inc

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Nov 2, 2021

07:00AM EDT Matinas BioPharma to Webcast Conference Call Discussing Third GlobeNewswire Inc

Oct 25, 2021

07:00AM EDT Matinas BioPharma Selected to Participate in the B. Riley Fall GlobeNewswire Inc

Oct 21, 2021

12:11PM EDT Matinas BioPharma Initiates Dosing In Phase 1 Study Of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501 Benzinga

07:00AM EDT Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential GlobeNewswire Inc

Sep 29, 2021

06:11AM EDT The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 6.00 A.M. EDT). RTTNews

Sep 28, 2021

06:02AM EDT The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 5.45 A.M. EDT). RTTNews

Sep 20, 2021

07:00AM EDT Ms. Corzo brings a 25+ year successful track record in biopharma, excelling in oncology drug development with Takeda, Sanofi Genzyme, and Eli Lilly GlobeNewswire Inc

Sep 14, 2021

07:00AM EDT Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, presented a Company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021. GlobeNewswire Inc

Sep 13, 2021

06:21AM EDT Matinas BioPharma Holdings, Inc. (MTNB) reported positive efficacy and safety data from the first two cohorts of patients in the ongoing EnACT study of MAT2203 for the treatment of cryptococcal meningitis. In Cohort 2, overall survival was 95% in 40 patients randomized to receiving MAT2203. RTTNews

06:03AM EDT Matinas BioPharma Announces Positive Data In EnACT Trial Of MAT2203 For Cryptococcal Meningitis RTTNews

06:02AM EDT Matinas BioPharma Announces Data In Ongoing EnACT TrialOof MAT2203 For Treatment Of Cryptococcal Meningitis; Mean Early Fungicidal Activity Exceeded Prespecified Primary Endpoint Threshold Benzinga

06:00AM EDT Step-down therapy with MAT2203 achieved effective clearance of fungal organisms; Mean Early Fungicidal Activity (EFA) was 0.38, exceeding the prespecified primary endpoint threshold target of >0.20 GlobeNewswire Inc

Aug 16, 2021

07:26AM EDT Matinas BioPharma Announces Issuance Of U.S. Patent Protecting MAT2203 To Treat Or Prevent Cryptococcus Infections RTTNews

07:00AM EDT Matinas BioPharma Announces Issuance of U.S. Patent Protecting GlobeNewswire Inc

Aug 10, 2021

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

06:36AM EDT Matinas BioPharma Hldgs Q2 EPS $(0.02) Beats $(0.03) Estimate Benzinga

06:31AM EDT Enrollment complete in second cohort of EnACT study of MAT2203 (oral amphotericin B) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) review of safety and efficacy data from second cohort anticipated September 2021 GlobeNewswire Inc

04:05AM EDT Earnings Scheduled For August 10, 2021 Benzinga

Aug 9, 2021

11:35AM EDT Matinas BioPharma Hldgs Earnings Preview Benzinga

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 3, 2021

07:30AM EDT Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a fireside chat as part of the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021 at 3:00 p.m. ET. The Company will also host investor meetings during the conference. GlobeNewswire Inc

Jun 23, 2021

10:48AM EDT Matinas BioPharma Hldgs: Return On Capital Employed Insights Benzinga

Jun 7, 2021

10:01AM EDT Return On Capital Employed Overview: Matinas BioPharma Hldgs Benzinga

May 20, 2021

08:00AM EDT Matinas will highlight progress across its lipid nanocrystal (LNC) delivery platform and associated pipeline programs GlobeNewswire Inc

May 10, 2021

10:09AM EDT Matinas BioPharma shares were trading higher after the company reported better-than-expected Q1 sales results. Benzinga

06:33AM EDT Matinas BioPharma Hldgs Q1 EPS $(0.03), Inline, Sales $33.33K Beat $20.00K Estimate Benzinga

06:30AM EDT Enrollment continues in second cohort of EnACT study of MAT2203 (oral amphotericin b) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data from second cohort anticipated Q3 2021 GlobeNewswire Inc

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

May 7, 2021

10:09AM EDT Matinas BioPharma Hldgs's Earnings: A Preview Benzinga

Apr 28, 2021

07:30AM EDT Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a fireside chat as part of the 7th Annual Truist Securities Life Sciences Summit on Wednesday, May 5, 2021 at 11:20 a.m. ET. The Company will also host investor meetings during the conference. GlobeNewswire Inc

Apr 27, 2021

07:30AM EDT Matinas BioPharma to Webcast Conference Call Discussing First GlobeNewswire Inc

Apr 8, 2021

07:30AM EDT Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 4:30 p.m. ET. The Company will also host investor meetings during the conference. GlobeNewswire Inc

Mar 29, 2021

06:31AM EDT Matinas BioPharma Hldgs Q4 EPS $(0.03), Inline Benzinga

06:30AM EDT Matinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics GlobeNewswire Inc

04:16AM EDT Earnings Scheduled For March 29, 2021 Benzinga

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 26, 2021

10:21AM EDT Matinas BioPharma Earnings Outlook Benzinga

Mar 15, 2021

07:00AM EDT Matinas BioPharma to Webcast Conference Call Discussing Fourth GlobeNewswire Inc

Mar 1, 2021

07:30AM EST Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the Barclays Global Healthcare Conference on Tuesday, March 9, 2021 at 4:45 p.m. ET. The Company will also host investor meetings during the conference. GlobeNewswire Inc

Feb 1, 2021

02:36PM EST Mid-Afternoon Market Update: Dow Jumps Over 300 Points; Viela Bio Shares Spike Higher Benzinga

06:32AM EST Matinas:Primary Endpoint Of Percent Change From Baseline To End Of Treatment In TG Did Not Meet Statistical Significance RTTNews

06:02AM EST UPDATE: Matinas BioPharma Announces 'LYPDISO demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa' Benzinga

06:02AM EST Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO Against Vascepa Benzinga

06:00AM EST LYPDISO demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa GlobeNewswire Inc

Jan 6, 2021

07:00AM EST Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the ICR Conference 2021 on Thursday, January 14, 2021 at 1:00 p.m. ET. GlobeNewswire Inc

Jan 4, 2021

07:20AM EST Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO as the Brand Name for MAT9001 Benzinga

07:00AM EST Matinas BioPharma Announces FDA Conditional Acceptance of GlobeNewswire Inc

Dec 7, 2020

06:59AM EST Matinas BioPharma Files Preliminary Proxy for Special Meeting of Stockholders Benzinga

06:59AM EST Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead's Antiviral Remdesivir Utilizing Matinas' LNC Platform Delivery Technology Benzinga

06:35AM EST Matinas BioPharma Announces Collaboration with the National GlobeNewswire Inc

06:30AM EST - Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock SplitPriorto January 26, 2022- GlobeNewswire Inc

Dec 1, 2020

07:17AM EST Matinas BioPharma Appoints Hui Liu As Chief Technology Officer RTTNews

07:00AM EST Matinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief GlobeNewswire Inc

Nov 20, 2020

07:01AM EST Matinas BioPharma Awarded up to $3.75M from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin For The Treatment of NTM Infections in Cystic Fibrosis Patients Benzinga

07:00AM EST Matinas BioPharma Awarded up to $3.75 Million from the Cystic GlobeNewswire Inc

Nov 19, 2020

04:15PM EST Matinas BioPharma to Participate in Annual Piper Sandler GlobeNewswire Inc

Nov 6, 2020

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

07:09AM EST Matinas BioPharma Hldgs Q3 EPS $(0.03), Inline, Sales $95.83K Beat $20.00K Estimate Benzinga

07:00AM EST EnACT study of MAT2203 in cryptococcal meningitis received unanimous Data and Safety Monitoring Board (DSMB)recommendation to proceed into second patient cohort GlobeNewswire Inc

03:33AM EST Earnings Scheduled For November 6, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 23, 2020

07:30AM EDT Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Friday, November 6, 2020 at 8:30 a.m. ET to discuss operational and financial results for the third quarter ended September 30, 2020. GlobeNewswire Inc

Oct 19, 2020

06:33AM EDT Matinas BioPharma Announces Unanimous DSMB Approval to Progress Into Second Cohort of Patients In The EnACT Study of MAT2203 For The Treatment of Cryptococcal Meningitis Benzinga

06:30AM EDT DSMB evaluated both safety and efficacy data in recommending cohort progression GlobeNewswire Inc

Sep 15, 2020

07:31AM EDT Matinas BioPharma Announces Positive End Of Phase 2 Meeting With FDA For MAT9001 In Severe Hypertriglyceridemia RTTNews

07:03AM EDT Matinas BioPharma Announces Positive End of Phase 2 Meeting with the FDA for MAT9001 in Severe Hypertriglyceridemia; Co. Announces FDA Agreed to Move Directly into Phase 3 Benzinga

07:00AM EDT Matinas BioPharma Announces Positive End of Phase 2 Meeting with GlobeNewswire Inc

Sep 14, 2020

07:11AM EDT Matinas BioPharma Appoints Natasha Giordano To Board RTTNews

07:00AM EDT Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the appointment of Natasha Giordano to its Board of Directors as an independent director and a member of the audit committee, effective Monday, September 14, 2020. GlobeNewswire Inc

Aug 27, 2020

04:28PM EDT Matinas BioPharma Announces That It Has Completed Its Enrollment In Its ENHANCE-IT Study Benzinga

04:05PM EDT Matinas BioPharma Completes Enrollment of ENHANCE-IT Study of GlobeNewswire Inc

Aug 26, 2020

07:00AM EDT Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview and host one-on-one meetings during two upcoming virtual investor conferences. GlobeNewswire Inc

Aug 20, 2020

07:00AM EDT Matinas BioPharma Announces Publication of Results from Phase 1 GlobeNewswire Inc

Aug 13, 2020

10:51AM EDT Aegis Capital Maintains Buy on Matinas BioPharma Hldgs, Raises Price Target to $3.5 Benzinga

Aug 10, 2020

04:42PM EDT Matinas BioPharma Hldgs Q2 EPS $(0.03), Inline Benzinga

04:05PM EDT ENHANCE-IT study of MAT9001 against Vascepa expected to be fully enrolled in August 2020; topline data anticipated Q1 2021 GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 7, 2020

11:00AM EDT Earnings Preview for Matinas BioPharma Hldgs Benzinga

Aug 4, 2020

07:00AM EDT Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a fireside chat during the BTIG Virtual Biotech Conference 2020 on Tuesday, August 11, 2020 at 9:00 a.m. ET. GlobeNewswire Inc

Jul 28, 2020

07:00AM EDT Matinas BioPharma Holdings, Inc. (Matinas BioPharma or the Company) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 4:30 p.m. ET to discuss operational and financial results for the second quarter ended June 30, 2020. GlobeNewswire Inc